This trial will study whether the combination of Endoscopic Ultrasound (EUS) Radiofrequency ablation (RFA) and Neoadjuvant chemotherapy (NAC) is a feasible and tolerable treatment for Pancreatic Ductal Adenocarcinoma (PDAC), and what effect it has on the tumor.
2 Primary · 3 Secondary · Reporting Duration: 4 months after the initiation of chemotherapy
15 Total Participants · 1 Treatment Group
Primary Treatment: Neoadjuvant chemotherapy (NAC) · No Placebo Group · Phase 2
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: